Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 12/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 11/20 | 0.60 |
| ▸ | ADRA2B | P18089 | 11/20 | 0.60 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.54 |
| ▸ | SCN1A | P35498 | 1/20 | 0.54 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.54 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.54 |
| ▸ | GBA1 | P04062 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2552221 | 0.91 | ADRA2C (0.59) | ADRA2CADRA2AADRA2BADRA1DADRA1A | |
| SCHEMBL2462133 | 0.85 | ADRA2C (0.52) | ADRA2CADRA2AADRA2BGBA1HTR1A | |
| SCHEMBL2544710 | 0.84 | ADRA2C (0.71) | ADRA2CADRA2AADRA2BADRA1DADRA1A | |
| SCHEMBL2544709 | 0.84 | ADRA2C (0.71) | ADRA2CADRA2AADRA2BADRA1DADRA1A | |
| SCHEMBL2548199 | 0.82 | ADRA2A (0.61) | ADRA2CADRA2AADRA2BADRA1DADRA1A | |
| SCHEMBL2454473 | 0.81 | ADRA2A (0.63) | ADRA2CADRA2AADRA2BADRA1DADRA1A | |
| SCHEMBL2548228 | 0.80 | ADRA2A (0.76) | ADRA2CADRA2AADRA2BADRA1DADRA1A | |
| SCHEMBL2549133 | 0.80 | ADRA2A (0.76) | ADRA2CADRA2AADRA2BADRA1DADRA1A | |
| SCHEMBL29791112 | 0.80 | ADRA2A (0.76) | ADRA2CADRA2AADRA2BADRA1DADRA1A | |
| SCHEMBL2548729 | 0.77 | GAA (0.59) | GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110262352-A1 | ARYL PIPERAZINE AND THEIR USE AS ALPHA2C ANTAGONISTS | ORION CORPORATION (FI) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262352-A1 | ARYL PIPERAZINE AND THEIR USE AS ALPHA2C ANTAGONISTS | ADRA2C, ADRA2A, HTR2C | ADRA2C 1/4885ADRA2A 2/4885ADRA2B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.